Director Rachel Humphrey of Pyxis Oncology, Inc. filed a Form 4 on November 6, 2026, disclosing the acquisition of a stock option covering 34,500 shares of common stock at an exercise price of $1.66 per share.

Key Highlights

  • Reporting person: Rachel Humphrey, identified as a Director of Pyxis Oncology, Inc.
  • Transaction date: November 6, 2026, with a transaction code of A (acquired).
  • Option grant: A stock option (right to buy) covering 34,500 shares of common stock was acquired at an exercise price of $1.66 per share.
  • Price paid: The price of the derivative security at acquisition was $0.
  • Expiration date: The option expires on November 6, 2036.
  • Vesting schedule: According to the filing, shares subject to the option "will vest in equal monthly installments through December 31, 2026, subject to the reporting person's continued service through the applicable vesting date."
  • Post-transaction holdings: Humphrey beneficially owns 34,500 derivative securities following the reported transaction, held directly.

Pyxis Oncology Director Humphrey Receives Stock Option Grant on November 6, 2026

According to the Form 4 filing, Rachel Humphrey, a director of Pyxis Oncology, Inc. (NASDAQ:PYXS), acquired a stock option granting the right to buy 34,500 shares of the company's common stock. The transaction was dated November 6, 2026, and the option was obtained at no cost, with an exercise price of $1.66 per share set at the time of the grant.

The filing discloses that the option carries an expiration date of November 6, 2036, giving a ten-year window from the grant date. The vesting terms, as described in the filing's explanatory footnote, provide that the shares subject to the option "will vest in equal monthly installments through December 31, 2026, subject to the reporting person's continued service through the applicable vesting date." Following this transaction, Humphrey's total beneficial ownership of derivative securities stands at 34,500, held directly, with no non-derivative securities reported in Table I of the filing.

The Form 4 was signed by Jitendra Wadhane as attorney-in-fact for Rachel Humphrey, also on November 6, 2026. The filing was submitted by one reporting person and does not indicate any amendment to a prior filing.

What Was Disclosed

Pyxis Oncology director Rachel Humphrey disclosed the acquisition of a stock option for 34,500 shares of common stock at a $1.66 exercise price, expiring November 6, 2036, with vesting in equal monthly installments through December 31, 2026.